logo logo

Preventing blood clots in cancer patients

Daily injections of nadroparin, a heparin, in cancer patients during chemotherapy decreased the risk of blood clots by 47%, according to a new study.

Patients who receive chemotherapy are at an increased risk for developing blood clots. Drugs that prevent clotting or anti-coagulants, can be given to reduce the risk of clots in cancer patients undergoing chemotherapy. Common anti-coagulant drugs include warfarin and heparin.

The blood clot study

The researchers followed 1,166 patients with advanced cancer. They were randomly divided into 2 groups:

  • received injections of nadroparin once a day.
  • received injections of a placebo once a day.

Treatment started on the first day of chemotherapy and continued for the duration of treatment.

The incidence of thromboembolic events was 2.1% in patients receiving nadroparin and 3.9% in those receiving placebo. Nadroparin appeared to be safe, with only five patients (0.7%) experiencing a major bleeding event.

Researchers observations

The researchers concluded that, “nadroparin reduces the incidence of thromboembolic events in cancer patients receiving chemotherapy.”

Related articles

Home INR monitoring for warfarin found as safe.

Take your medication with water not juice researchers recommend.


bottom KellieMyHS

About Kellie

Kellie is 37 years old and together with her brother Steve makes up the My Health Software team.

She helps on the websites and gathering news for the programs. Kellie worked in the medical industry prior to having her two children (8 and 6) and has a strong interest in self awareness and management of health conditions.


News "home delivered"

Note: These news headlines are now automatically displayed on the home page of the My Health Software applications for Windows.

The news is updated regularly, and you can click through to these items to read more.